Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2024-06-14 00:00:00 ET · period of report 2024-06-12 · accession 0001610717-24-000339 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-14 | 2024-06-12 | CTMX | Ogden Christopher | CFO | A - Grant | $0.00 | +17.5K | 103.2K | +20% | $0 |
| D | 2024-06-14 | 2024-06-12 | CTMX | Ogden Christopher | CFO | A - Grant | $0.00 | +75.0K | 75.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-12 | A | A | 17,500 | $0.00 | 103,186 | D | — | — | (F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on June 12 of each year, with the first 1/3rd vesting on June 12, 2025, subject to the Reporting Person continuing as a service provider through each such date. (F2) Includes 77,810 RSUs. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-06-12 | A | A | 75,000 | $0.00 | 75,000 | D | $1.49 · — to 2034-06-11 | 75,000 Common Stock | (F3) 1/48th of the shares subject to the option vest on each monthly anniversary measured from June 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |